JG
STML

Jefferies Group’s Stemline Therapeutics, Inc. STML Stock Holding History

Jefferies Group’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-265
Closed -$3K – 3351
2015
Q2 		$3K Buy
+265
New +$3.68K ﹤0.01% 3113

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jefferies Group's STML Position: Q3 2015 in Review

Jefferies Group sold out of Stemline Therapeutics, Inc. (STML) in Q3 2015, closing a stake of 265 shares — an estimated $3K sold.

Jefferies Group first reported a position in STML in Q2 2015 and held it in 1 quarter. The position peaked at $3K in Q2 2015. 62 funds tracked by Wall St. Rank hold STML as of Q3 2015.

  • Jefferies Group reported no remaining Stemline Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
  • Jefferies Group sold 265 Stemline Therapeutics, Inc. shares in Q3 2015, an estimated $3K.
  • Jefferies Group first reported a position in Stemline Therapeutics, Inc. in Q2 2015 and held it in 1 quarter.
  • Jefferies Group's Stemline Therapeutics, Inc. position peaked at $3K in Q2 2015.
  • 62 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q3 2015.

Based on Jefferies Group's 13F filing for Q3 2015, filed 13 Nov 2015.